The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
Open accessAbstract
OBJECTIVE: Eosinophilic oesophagitis (EoO) is a clinicopathological condition defined by proton pump inhibitor-refractory oesophageal symptoms combined with oesophageal eosinophilia. The pharmacodynamic effect of mepolizumab (a humanised anti-interleukin-5 monoclonal antibody) in EoO was evaluated. METHODS: Eleven adults with active EoO (>20 peak eosinophil number/high power field (hpf) and dysphagia) were randomised to 750 mg of mepolizumab (n = 5) or placebo (n = 6) and received two intravenous infusions, 1 week apart. Those not in complete remission (<5 peak eosinophil number/hpf) after 8 weeks received two further doses 4 weeks apart, 1500 mg of mepolizumab or placebo. The effect of mepolizumab was assessed clinically, endoscopically, histologically, and via blood and tissue biomarkers. RESULTS: As assessed by immunofluorescence, a marked reduction of mean oesophageal eosinophilia (p = 0.03) was seen in the mepolizumab group (-54%) compared with the placebo group (-5%) 4 weeks after initiation of treatment. No further reduction of eosinophil numbers was observed in response to the two additional infusions in either group. Mepolizumab reduced tenascin C (p = 0.033) and transforming growth factor beta1 (p = 0.05) expression in the oesophageal epithelial layer 13 weeks after initiation of treatment. Clinically, limited improvement of symptoms was seen, although a trend was seen between 4 and 13 weeks after initiation of mepolizumab treatment. Mepolizumab was well tolerated. CONCLUSIONS: Mepolizumab significantly reduced eosinophil numbers in oesophageal tissues in adult patients with active EoO, and changes in the expression of molecules associated with oesophageal remodelling were reversed. Minimal clinical improvement was achieved in a subgroup of patients with EoO. Mepolizumab had an acceptable safety profile, even at the high 1500 mg dose level. TRIAL REGISTRATION NUMBER: NCT00274703.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W., Sousa, A., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,871
Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Furuta, G. T., Liacouras, C. A., Collins, M. H., Gupta, S. K., Justinich, C., Putnam, P. E., Bonis, P., Hassall, E., Straumann, A., & Rothenberg, M. E. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.017 · Cited by 1,673
Self-citationMepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
Nair, P., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O'Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,356
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense
Yousefi, S., Gold, J. A., Andina, N., Lee, J. J., Kelly, A. M., Kozlowski, E., Schmid, I., Straumann, A., Reichenbach, J., Gleich, G. J., et al. (2008) · Nature Medicine · doi:10.1038/nm.1855 · Cited by 967
Self-citationEotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis
Blanchard, C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26679 · Cited by 870
Flood-Page, P., Menzies-Gow, A., Phipps, S., Ying, S., Wangoo, A., Ludwig, M. S., Barnes, N., Robinson, D., & Kay, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17974 · Cited by 841
Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808
Noel, R. J., Putnam, P. E., & Rothenberg, M. E. (2004) · New England Journal of Medicine · doi:10.1056/nejm200408263510924 · Cited by 721
Straumann, A., Spichtin, H.-P., Grize, L., Bucher, K. A., Beglinger, C., & Simon, H.-U. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.024 · Cited by 710
Self-citationAn etiological role for aeroallergens and eosinophils in experimental esophagitis
Mishra, A., Hogan, S. P., Brandt, E. B., & Rothenberg, M. E. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10224 · Cited by 626
Mire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 624
Konikoff, M. R., Noel, R. J., Blanchard, C., Kirby, C., Jameson, S. C., Buckmeier, B. K., Akers, R., Cohen, M. B., Collins, M. H., Assa’ad, A. H., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.033 · Cited by 585
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
Rothenberg, M. E., Klion, A. D., Roufosse, F. E., Kahn, J. E., Weller, P. F., Simon, H.-U., Schwartz, L. B., Rosenwasser, L. J., Ring, J., Griffin, E. F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa070812 · Cited by 583
Self-citationIdiopathic eosinophilic esophagitis is associated with a TH2-type allergic inflammatory response
Straumann, A., Bauer, M., Fischer, B., Blaser, K., & Simon, H.-U. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.119917 · Cited by 554
Self-citationPrimary Eosinophilic Esophagitis in Children: Successful Treatment with Oral Corticosteroids
Liacouras, C. A., Wenner, W. J., Brown, K., & Ruchelli, E. (1998) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.1998.tb00803.x · Cited by 499
Kips, J. C., O'Connor, B. J., Langley, S. J., Woodcock, A., Kerstjens, H. A. M., Postma, D. S., Danzig, M., Cuss, F., & Pauwels, R. A. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-525oc · Cited by 494
Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis
Gonsalves, N., Policarpio-Nicolas, M., Zhang, Q., Rao, M. S., & Hirano, I. (2006) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2006.04.037 · Cited by 491
Anti–IL-5 (mepolizumab) therapy for eosinophilic esophagitis
Stein, M. L., Collins, M. H., Villanueva, J. M., Kushner, J. P., Putnam, P. E., Buckmeier, B. K., Filipovich, A. H., Assa'ad, A. H., & Rothenberg, M. E. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.09.007 · Cited by 459
Nasal IL-5 levels determine the response to anti–IL-5 treatment in patients with nasal polyps
Gevaert, P., Lang-Loidolt, D., Lackner, A., Stammberger, H., Staudinger, H., Van Zele, T., Holtappels, G., Tavernier, J., van Cauwenberge, P., & Bachert, C. (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.05.031 · Cited by 442
Esophageal remodeling in pediatric eosinophilic esophagitis
Aceves, S. S., Newbury, R. O., Dohil, R., Bastian, J. F., & Broide, D. H. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.10.016 · Cited by 432
Teitelbaum, J. E., Fox, V. L., Twarog, F. J., Nurko, S., Antonioli, D., Gleich, G., Badizadegan, K., & Furuta, G. T. (2002) · Gastroenterology · doi:10.1053/gast.2002.32998 · Cited by 414
Schaefer, E. T., Fitzgerald, J. F., Molleston, J. P., Croffie, J. M. B., Pfefferkorn, M. D., Corkins, M. R., Lim, J. D., Steiner, S. J., & Gupta, S. K. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.11.008 · Cited by 413
Eosinophilic esophagitis: Escalating epidemiology?
Straumann, A., & Simon, H.-U. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.006 · Cited by 393
Self-citationSpechler, S. J., Genta, R. M., & Souza, R. F. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01179.x · Cited by 358
Eosinophilic oesophagitis: a novel treatment using Montelukast
Attwood, S. E. A., Lewis, C. J., Bronder, C. S., Morris, C. D., Armstrong, G. R., & Whittam, J. (2003) · Gut · doi:10.1136/gut.52.2.181 · Cited by 341
IL-5 Promotes Eosinophil Trafficking to the Esophagus
Mishra, A., Hogan, S. P., Brandt, E. B., & Rothenberg, M. E. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2464 · Cited by 335
Treatment of Eosinophilic Esophagitis with Inhaled Corticosteroids
Faubion, W. A., Perrault, J., Burgart, L. J., Zein, N. N., Clawson, M., & Freese, D. K. (1998) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/j.1536-4801.1998.tb01105.x · Cited by 322
Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis
Noel, R. J., Putnam, P. E., Collins, M. H., Assa’ad, A. H., Guajardo, J. R., Jameson, S. C., & Rothenberg, M. E. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00240-x · Cited by 269
Use of an Anti–Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis
Plötz, S.-G., Simon, H.-U., Darsow, U., Simon, D., Vassina, E., Yousefi, S., Hein, R., Smith, T., Behrendt, H., & Ring, J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031261 · Cited by 259
Self-citationAnti-CD20 (rituximab) treatment improves atopic eczema
Simon, D., Hösli, S., Kostylina, G., Yawalkar, N., & Simon, H.-U. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.11.016 · Cited by 255
Self-citationEsophageal Remodeling Develops as a Consequence of Tissue Specific IL-5-Induced Eosinophilia
Mishra, A., Wang, M., Pemmaraju, V. R., Collins, M. H., Fulkerson, P. C., Abonia, J. P., Blanchard, C., Putnam, P. E., & Rothenberg, M. E. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.10.002 · Cited by 255
Topical Corticosteroid Treatment of Dysphagia Due to Eosinophilic Esophagitis in Adults
Arora, A. S., Perrault, J., & Smyrk, T. C. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.7.830 · Cited by 213
Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases
Simon, D., Marti, H., Heer, P., Simon, H.-U., Braathen, L. R., & Straumann, A. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2005.01.017 · Cited by 207
Self-citationAnti–TNF-α (infliximab) therapy for severe adult eosinophilic esophagitis
Straumann, A., Bussmann, C., Conus, S., Beglinger, C., & Simon, H.-U. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.06.012 · Cited by 190
Self-citationStein, M., Villanueva, J. M., Buckmeier, B. K., Yamada, Y., Filipovich, A. H., Assa’ad, A., & Rothenberg, M. E. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.033 · Cited by 156
Kim, Y., Prussin, C., Martin, B., Law, M. A., Haverty, T. P., Nutman, T. B., & Klion, A. D. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.08.027 · Cited by 113
Review article: the pathogenesis and management of eosinophilic oesophagitis
Furuta, G. T., & Straumann, A. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02984.x · Cited by 101
Self-citationEpidemiology and Etiology of Eosinophilic Esophagitis
Chehade, M., & Sampson, H. A. (2007) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2007.09.002 · Cited by 63
Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab
(2008) · New England Journal of Medicine · doi:10.1056/nejmx080014 · Cited by 19
Cited by
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
Liacouras, C. A., Furuta, G. T., Hirano, I., Atkins, D., Attwood, S. E., Bonis, P. A., Burks, A. W., Chehade, M., Collins, M. H., Dellon, E. S., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.02.040 · Cited by 2,073
Self-citationDellon, E. S., Gonsalves, N., Hirano, I., Furuta, G. T., Liacouras, C. A., & Katzka, D. A. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.71 · Cited by 1,159
Eosinophils: changing perspectives in health and disease
Rosenberg, H. F., Dyer, K. D., & Foster, P. S. (2013) · Nature Reviews Immunology · doi:10.1038/nri3341 · Cited by 989
Food allergy: A practice parameter update—2014
Sampson, H. A., Aceves, S., Bock, S. A., James, J., Jones, S., Lang, D., Nadeau, K., Nowak-Wegrzyn, A., Oppenheimer, J., Perry, T. T., et al. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.05.013 · Cited by 845
Spergel, J. M., Rothenberg, M. E., Collins, M. H., Furuta, G. T., Markowitz, J. E., Fuchs, G., O’Gorman, M. A., Abonia, J. P., Young, J., Henkel, T., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.044 · Cited by 556
Metadata
- Authors
- Straumann, A., Conus, S., Grzonka, P., Kita, H., Kephart, G., Bussmann, C., Beglinger, C., Smith, D. A., Patel, J., Byrne, M., & Simon, H.-U.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2009-10-13
- Volume
- 59
- Issue
- 01
- Pages
- 21-30
- ISSN
- 0017-5749 (ISSN-L)
- OpenAlex
- W2098392838
- Cited by
- 598
- References
- 40
- FWCI
- 35.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.